ATTR AmyloidosisArchives
Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
ATTR Amyloidosis 3 min.
Data are available upon reasonable request. https://doi.org/10.1136/heartjnl-2024-324826...
The efficacy and safety of specific therapies for cardiac Transthyretin-mediated amyloidosis: a systematic review and meta-analysis of randomized trials
ATTR Amyloidosis 5 min.
Transthyretin (TTR) amyloidosis (ATTR) is a disease characterized by the deposition of misfolded TTR monomers in vital organs. This condition arises either from destabilizing mutations in hereditary ATTR (hATTR) or from an age-associated mechanism in wild-type ATTR (wtATTR), frequently involving the...
Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis
ATTR Amyloidosis 4 min.
Transthyretin cardiac amyloidosis (ATTR‐CA) is a rare, progressive, and ultimately fatal disease that results from the misfolding and aggregation of amyloidogenic transthyretin (TTR) proteins in the myocardial extracellular space. ATTR‐CA can result from an idiopathic subtype, also known...
Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care
ATTR Amyloidosis 5 min.
This article is published with digital features, including a video , to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.28497332. ...
Elucidation of the mechanism of amyloid A and transthyretin formation using mass spectrometry-based absolute quantification.
ATTR Amyloidosis NaN min.
Amyloidosis is triggered by the truncation of amyloid precursor proteins, causing organ damages. While previous studies found the truncation of amyloid A (AA) and amyloid transthyretin (ATTR) occurs in C- and N-terminal, respectively, the detailed mechanism of the fibril formation remains unclear. Liquid...
